Pre-market: 6681.HK Brainaurora-b HK$4.67 Feb 2026 HKSE earnings 25 Feb: watch

The 6681.HK stock opens pre-market at HK$4.67, a -2.71% move from the prior close as investors position ahead of Brainaurora-b’s earnings due 25 February 2026. Market attention is on revenue trends, cash flow, and any clinical or regulatory updates for its digital therapy products. We focus on near-term catalysts and valuation ahead of the report and what to watch in trading in Hong Kong (HKSE).

Earnings Preview: 6681.HK stock ahead of 25 Feb report

Brainaurora-b (6681.HK) reports on 25 Feb 2026. Consensus detail is thin for this newly listed company, so management commentary will matter more than earnings beats. The company’s trailing EPS is -0.19 and the TTM PE reads -25.63, which reflects ongoing losses and heavy R&D investment.

Investors should watch guidance on clinical rollouts, revenue recognition for its DTx platform, and any conversion of pilot programs to recurring contracts. Any clear revenue acceleration or narrowing of losses could re-rate the stock in the short term.

Price action and technical setup for 6681.HK stock

Pre-market the stock is at HK$4.67, with an intraday range yesterday of HK$4.67–HK$4.96 and an open at HK$4.86. Year high is HK$17.79 and year low is HK$3.77. Market capitalization stands near HK$6.61B and volume is 2,496,000 vs average volume 22,354,428, showing lighter liquidity.

Technicals show RSI 42.38 and MACD histogram slightly positive, suggesting muted momentum. The 50-day average is HK$5.88 and the 200-day average is HK$6.45, so the price sits below key moving averages. Watch for volatility spikes around the earnings release.

Financial health, margins and key risks

Key metrics show revenue per share HK$0.14 and net income per share -0.22 (TTM). Cash per share is HK$0.38 and the current ratio is 0.70, indicating tight short-term liquidity.

Operational risks include long receivables with days sales outstanding at 400.54 and high R&D spending at 97.64% of revenue. Those factors raise execution risk for scaling commercial deployment and maintaining working capital without equity or debt raises.

Meyka AI grade and analyst context for 6681.HK stock

Meyka AI rates 6681.HK with a score out of 100: 65.20 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company’s score reflects growth potential in medical DTx but offsets include weak margins and liquidity constraints.

Independent third-party ratings are mixed; a recent company rating dated 16 Feb 2026 showed a D+ on aggressive fundamental metrics. Use both views to frame risk-adjusted position sizing ahead of earnings.

Meyka AI’s forecast and price targets for 6681.HK stock

Meyka AI’s forecast model projects a 12-month price of HK$5.10 and a monthly projection of HK$5.36. Versus the current price HK$4.67, the 12-month projection implies an upside of 9.21% and the monthly projection implies 14.77% upside. Forecasts are model-based projections and not guarantees.

Scenario targets: conservative HK$3.90 (downside -16.50%), base HK$5.10 (upside 9.21%), bull HK$7.50 (upside 60.60%). These targets reflect event risk, thin liquidity, and sector comparables in healthcare technology.

Pre-market trading checklist and earnings watch points

In pre-market trade focus on: reported revenue and cash flow, contract wins or pilot-to-commercial conversions, and any regulatory clarity on DTx reimbursement. Low relative volume (relVolume 0.10) means price moves can be amplified by modest orders.

Check liquidity and set execution plans. For Hong Kong (HKSE) trading, confirm order size against average daily volume and monitor news flow. For background context see the recent sector comparison on investing.com source and our internal page at Meyka 6681.HK page.

Final Thoughts

Key takeaways: 6681.HK stock trades at HK$4.67 in pre-market Hong Kong trading with earnings due 25 Feb 2026. The company shows promising digital therapy assets but sells at negative EPS (-0.19) and tight liquidity (current ratio 0.70). Meyka AI’s forecast model projects HK$5.10 over 12 months, an implied 9.21% increase versus today’s price, but forecasts are model-based projections and not guarantees. Analysts and investors should treat earnings as a catalyst for short-term volatility rather than a definitive value signal. Watch guidance on contract rollouts, receivables improvement, and any near-term financing updates. Use the company’s sector context in Hong Kong healthcare and compare valuation metrics before adjusting position size. Meyka AI provides this data-driven snapshot as an AI-powered market analysis platform to help frame the risks and opportunities ahead of the report.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.